PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis

被引:458
作者
Jiang, Bing-Hua [1 ,2 ,3 ]
Liu, Ling-Zhi [1 ,2 ]
机构
[1] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA
[2] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA
[3] Nanjing Med Univ, Dept Pathol, Ctr Canc, Nanjing 210029, Jiangsu, Peoples R China
来源
ADVANCES IN CANCER RESEARCH, VOL 102 | 2009年 / 102卷
关键词
ENDOTHELIAL-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; PHASE-II TRIAL; NF-KAPPA-B; HYPOXIA-INDUCIBLE FACTOR; ADVANCED SOLID TUMORS; RENAL-CELL CARCINOMA; RECURRENT MALIGNANT GLIOMA; SMOOTH-MUSCLE-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET;
D O I
10.1016/S0065-230X(09)02002-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphatidylinositol 3-kinase (PI3K) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signaling pathway play an important role in multiple cellular functions such as cell metabolism, proliferation, cell-cycle progression, and survival. PI3K is activated by growth factors and angiogenesis inducers such is vascular endothelial growth factor (VEGF) and angiopoietins. The amplification and Mutations of PI3K and the loss of the tumor suppressor PTEN are common in various kinds of human solid tumors. The genetic alterations of upstream and downstream of PI3K signaling molecules such as receptor tyrosine kinases and AKT, respectively, are also frequently altered in human cancer. PI3K signaling regulates tumor growth and angiogenesis by activating AKT and other targets, and by inducing HIF-1 and VEGF expression. Angiogenesis is required for tumor growth and metastasis. In this review, we highlight the recent studies on the roles and mechanisms of PI3K and PTEN in regulating tumorigenesis and angiogenesis, and the roles of the downstream targets of PI3K for transmitting the signals. We also discuss the crosstalk of these signaling molecules and Cellular events during tumor growth, metastasis, and tumor angiogenesis. Finally, we Summarize the potential applications of PI3K, AKT, and mTOR inhibitors and their Outcome in clinical trials for cancer treatment. (C) 2009 Elsevier Inc.
引用
收藏
页码:19 / 65
页数:47
相关论文
共 278 条
[21]   Mutation of the PIK3CA gene in ovarian and breast cancer [J].
Campbell, IG ;
Russell, SE ;
Choong, DYH ;
Montgomery, KG ;
Ciavarella, ML ;
Hooi, CSF ;
Cristiano, BE ;
Pearson, RB ;
Phillips, WA .
CANCER RESEARCH, 2004, 64 (21) :7678-7681
[22]   The phosphoinositide 3-kinase pathway [J].
Cantley, LC .
SCIENCE, 2002, 296 (5573) :1655-1657
[23]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[24]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[25]   Akt-mediated activation of HIF-1 in pulmonary vascular endothelial cells by S-nitrosoglutathione [J].
Carver, D. Jeannean ;
Gaston, Benjamin ;
Deronde, Kimberly ;
Palmer, Lisa A. .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2007, 37 (03) :255-263
[26]   The role of VEGF receptors in angiogenesis;: complex partnerships [J].
Cébe-Suarez, S ;
Zehnder-Fjällman, A ;
Ballmer-Hofer, K .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (05) :601-615
[27]   Cobalt induces hypoxia-inducible factor-1α expression in airway smooth muscle cells by a reactive oxygen species- and PI3K-dependent mechanism [J].
Chachami, G ;
Simos, G ;
Hatziefthimiou, A ;
Bonanou, S ;
Molyvdas, PA ;
Paraskeva, E .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2004, 31 (05) :544-551
[28]   Dual Inhibition of PI3Kα and mTOR as an Alternative Treatment for Kaposi's Sarcoma [J].
Chaisuparat, Risa ;
Hu, Jiadi ;
Jham, Bruno C. ;
Knight, Zachary A. ;
Shokat, Kevan M. ;
Montaner, Silvia .
CANCER RESEARCH, 2008, 68 (20) :8361-8368
[29]   Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer [J].
Chan, S ;
Scheulen, ME ;
Johnston, S ;
Mross, K ;
Cardoso, F ;
Dittrich, C ;
Eiermann, W ;
Hess, D ;
Morant, R ;
Semiglazov, V ;
Borner, M ;
Salzberg, M ;
Ostapenko, V ;
Illiger, HJ ;
Behringer, D ;
Bardy-Bouxin, N ;
Boni, J ;
Kong, S ;
Cincotta, M ;
Moore, L .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5314-5322
[30]   Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit [J].
Chan, TO ;
Rodeck, U ;
Chan, AM ;
Kimmelman, AC ;
Rittenhouse, SE ;
Panayotou, G ;
Tsichlis, PN .
CANCER CELL, 2002, 1 (02) :181-191